Healthcare / Pharmaceutical RetailersTaipei Exchange
$5.57
-0.15 (-2.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-162.8M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.9B
P/E
69.6x
↑EV/EBITDA
35.0x
↑ROE
11.9%
↑Gross Margin
62.1%
↑Debt/Equity
0.86
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+79.1%
FCF CAGR
—
FCF margin
-25.6%
FCF / Net income
-3.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $635.9M · net income $42.9M · FCF $-162.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $635.9M | $635.9M | $618.2M | $289.9M | $110.6M |
| Net Income | $42.9M | $42.9M | $-96.8M | $-12.9M | $2.8M |
| EBITDA | $91.0M | $91.0M | $-77.2M | $-10.5M | $7.0M |
| EPS | — | — | -0.19 | -0.04 | 0.01 |
| Gross Margin | 62.1% | 62.1% | 69.6% | 74.0% | 76.1% |
| Operating Margin | -21.9% | -21.9% | -12.5% | -4.9% | 1.7% |
| Net Margin | 6.8% | 6.8% | -15.7% | -4.5% | 2.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.86 | 0.86 | 1.10 | 0.01 | 0.23 |
| Current Ratio | 1.78 | 1.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-162.8M | $-162.8M | $-325.7M | $-18.9M | $10.7M |
| Returns | |||||
| ROE | 11.9% | 11.9% | -38.5% | -4.4% | 4.7% |
| Valuation | |||||
| P/E | 69.63 | 69.63 | — | — | — |
| EV/EBITDA | 34.97 | 34.97 | — | — | — |
| P/B | 8.09 | 8.09 | 13.89 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 2.9% | 2.9% | 113.2% | 162.0% | — |
| EPS Growth | — | — | -376.3% | -500.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.19 → n/d
Residual
-4.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.